Login
Home
Charts
Search
Watchlist
Products

Accretion Nutraveda Ltd

ANL·BSE
₹303.00+2.36%Tue, 22 Sept '26 15:08
Industry:Pharma - Formulators
Indices:

Accretion Nutraveda Ltd

ANL
BSE
₹303.00
+2.36%
|Tue, 22 Sept '26 15:08
SOICxStockScans Reports
Industry
Pharma - Formulators
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹219Cr
Close
Close Price
₹303.00
Industry
Industry
Pharma - Formulators
PE
Price To Earnings
66.89
PS
Price To Sales
6.53
Revenue
Revenue
₹34Cr
Rev Gr TTM
Revenue Growth TTM
110.02%
PAT Gr TTM
PAT Growth TTM
102.73%

Quarterly Results

Standalone
Numbers
Percentage
QuarterSep 2024Mar 2025Sep 2025Mar 2026
Revenue
RevenueCr
5111420
Growth YoY
Revenue Growth YoY%
173.080.1
Expenses
ExpensesCr
481116
Operating Profit
Operating ProfitCr
1334
OPM
OPM%
22.323.823.518.3
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
0000
Depreciation
DepreciationCr
0000
PBT
PBTCr
1233
Tax
TaxCr
0011
PAT
PATCr
1223
Growth YoY
PAT Growth YoY%
198.756.4
NPM
NPM%
15.215.816.613.8
EPS
EPS₹
0.00.00.04.5
QuarterSep 2024Mar 2025Sep 2025Mar 2026
Revenue
RevenueCr
5111420
Growth YoY
Revenue Growth YoY%
173.080.1
Expenses
ExpensesCr
481116
Operating Profit
Operating ProfitCr
1334
OPM
OPM%
22.323.823.518.3
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
0000
Depreciation
DepreciationCr
0000
PBT
PBTCr
1233
Tax
TaxCr
0011
PAT
PATCr
1223
Growth YoY
PAT Growth YoY%
198.756.4
NPM
NPM%
15.215.816.613.8
EPS
EPS₹
0.00.00.04.5

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
351634
Growth
Revenue Growth%
72.4219.7110.0
Expenses
ExpensesCr
241227
Operating Profit
Operating ProfitCr
1147
OPM
OPM%
21.424.423.320.5
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
0001
Depreciation
DepreciationCr
0000
PBT
PBTCr
0136
Tax
TaxCr
0011
PAT
PATCr
0135
Growth
PAT Growth%
192.9204.3102.7
NPM
NPM%
9.716.415.615.1
EPS
EPS₹
7.822.86.99.3
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
351634
Growth
Revenue Growth%
72.4219.7110.0
Expenses
ExpensesCr
241227
Operating Profit
Operating ProfitCr
1147
OPM
OPM%
21.424.423.320.5
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
0001
Depreciation
DepreciationCr
0000
PBT
PBTCr
0136
Tax
TaxCr
0011
PAT
PATCr
0135
Growth
PAT Growth%
192.9204.3102.7
NPM
NPM%
9.716.415.615.1
EPS
EPS₹
7.822.86.99.3

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
0007
Reserves
ReservesCr
01528
Current Liabilities
Current LiabilitiesCr
2333
Non Current Liabilities
Non Current LiabilitiesCr
1124
Total Liabilities
Total LiabilitiesCr
451142
Current Assets
Current AssetsCr
33930
Non Current Assets
Non Current AssetsCr
11212
Total Assets
Total AssetsCr
451142
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
0007
Reserves
ReservesCr
01528
Current Liabilities
Current LiabilitiesCr
2333
Non Current Liabilities
Non Current LiabilitiesCr
1124
Total Liabilities
Total LiabilitiesCr
451142
Current Assets
Current AssetsCr
33930
Non Current Assets
Non Current AssetsCr
11212
Total Assets
Total AssetsCr
451142

Cash Flow

Standalone
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
10-2-9
Investing Cash Flow
Investing Cash FlowCr
00-1-15
Financing Cash Flow
Financing Cash FlowCr
-10325
Net Cash Flow
Net Cash FlowCr
0001
Free Cash Flow
Free Cash FlowCr
10-3-15
CFO To PAT
CFO To PAT%
242.828.0-88.6-185.9
CFO To EBITDA
CFO To EBITDA%
109.618.8-59.5-136.7
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
10-2-9
Investing Cash Flow
Investing Cash FlowCr
00-1-15
Financing Cash Flow
Financing Cash FlowCr
-10325
Net Cash Flow
Net Cash FlowCr
0001
Free Cash Flow
Free Cash FlowCr
10-3-15
CFO To PAT
CFO To PAT%
242.828.0-88.6-185.9
CFO To EBITDA
CFO To EBITDA%
109.618.8-59.5-136.7

Ratios

Standalone
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
151219
Price To Earnings
Price To Earnings
29.766.9
Price To Sales
Price To Sales
4.56.5
Price To Book
Price To Book
4.26.2
EV To EBITDA
EV To EBITDA
21.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
35.336.129.825.725.7
OPM
OPM%
21.424.423.320.520.5
NPM
NPM%
9.716.415.615.115.1
ROCE
ROCE%
21.435.439.417.017.0
ROE
ROE%
106.775.849.514.314.3
ROA
ROA%
6.917.723.712.112.1
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
151219
Price To Earnings
Price To Earnings
29.766.9
Price To Sales
Price To Sales
4.56.5
Price To Book
Price To Book
4.26.2
EV To EBITDA
EV To EBITDA
21.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
35.336.129.825.725.7
OPM
OPM%
21.424.423.320.520.5
NPM
NPM%
9.716.415.615.115.1
ROCE
ROCE%
21.435.439.417.017.0
ROE
ROE%
106.775.849.514.314.3
ROA
ROA%
6.917.723.712.112.1
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Accretion Nutraveda Ltd

  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/szk9dghsgatj0tc7ih01ftrr.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/mwqlnrouvveubt3slfqyh7nk.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies